関連する実験動画
Updated: May 2, 2026

08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
12.8K
潜在的免疫光学療法剤としてのルテシウム・テクサフィリン-セレコキシブ結合物
Jusung An1, Kong-Peng Lv2,3, Calvin V Chau4
1Department of Chemistry, Korea University, Seoul 02841, Korea.
Journal of the American Chemical Society
|July 3, 2024
まとめ
免疫光力学療法 (IPDT) はがん治療において有望である. Ex-apt@LuCXBという新しいナノ光敏感剤は,がん幹細胞を標的とし,IPDTを増幅し,臨床前モデルで有意な抗腫瘍効果を示しています.
科学分野:
- 腫瘍学
- ナノ医療
- 写真化学
背景:
- 免疫フォトダイナミック療法 (IPDT) は有望ながん治療法である.
- 新種の光敏感剤は 腫瘍を完全に根絶し 再発しないようにするために不可欠です
研究 の 目的:
- IPDTのための新しい光敏感剤コンジュガート,LuCXBを開発し,評価する.
- アプタマー機能化されたエクスソームベースのナノ光敏感剤 (Ex-apt@LuCXB) を作成し,がん幹細胞を標的とし,インビボ効果を高める.
主な方法:
- セレコキシブの結合体であるLuCXBとルテシウムテクサフィリン核の合成.
- Ex-apt@LuCXBをCD133+がん幹細胞に標的として投与する.
- 肝臓と乳がんのマウスモデルにおける光敏感性,生物適合性,腫瘍標的化,および治療効果の評価.
主要な成果:
- LuCXBは730nmの光照射でタイプI光ダイナミック経路を介して超酸化基を生成します.
- Ex-apt@LuCXBは良好な光敏感性,生物互換性,腫瘍標的性を示した.
- Ex- apt@ LuCXBは,マウスモデルにおいて,相乗効果の抗血管新生と光免疫療法により,腫瘍の成長を有意に抑制した.
結論:
- Ex-apt@LuCXBは,がん幹細胞を標的としたIPDTの効果的なナノ光敏感剤です.
- 観察された治療効果は,抗血管新生と光誘発がん免疫療法の組み合わせによるものです.
- このアプローチは腫瘍を完全に根絶し 再発を予防する可能性を秘めています
関連する概念動画
Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692

